Combining biochemical and ultrasonographic markers in predicting preeclampsia: A systematic review;Combinaison de marqueurs biochimiques et échographiques pour la prediction de la prééclampsie: Une revue systématique

Annales de Biologie Clinique

Volumn 69, Issue 3, 2011, Pages 257-271

  Giguère, Yves ^a,b   Charland, Marc ^a   Bujold, Emmanuel ^a,b   Bernard, Nathalie ^a   Grenier, Sonya ^a   Rousseau, François ^a,b   Lafond, Julie ^d   Légaré, France ^a,c   Forest, Jean Claude ^a,b  

^a Université Laval   (Canada)

^b Department of Medical Biology ^*  (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

^d UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

Author keywords

Biomarker; Prediction; Preeclampsia; Ultrasonography

Indexed keywords

BIOLOGICAL MARKER;

BLOOD; ECHOGRAPHY; FEMALE; HUMAN; PREDICTIVE VALUE; PREECLAMPSIA; PREGNANCY; REVIEW;

BIOLOGICAL MARKERS; FEMALE; HUMANS; PRE-ECLAMPSIA; PREDICTIVE VALUE OF TESTS; PREGNANCY;

EID: 79958097391     PISSN: 00033898     EISSN: 19506112     Source Type: Journal    
DOI: 10.1684/abc.2011.0572     Document Type: Review

References (72)

1. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005 ; 365: 785-99. (Pubitemid 40311367)
2. Lewis G. Confidential enquiry into maternal and child health. Why mothers die 2000-2002: the sixth report of the confidential enquiries into maternal deaths in the United Kingdom. Londres: RCOG, 2004
3. Moodley J. Maternal deaths due to hypertensive disorders in pregnancy: saving Mothers report 2002-2004. Cardiovasc J Afr 2007 ; 18: 358-61. (Pubitemid 351300618)
4. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001 ; 20: IX-XIV. (Pubitemid 32672922)
5. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000 ; 183: S1-S22.
6. Forest JC, Girouard J, Masse J, Moutquin JM, Kharfi A, Ness RB, et al. Early occurrence of metabolic syndrome after hypertension in pregnancy. Obstet Gynecol 2005 ; 105: 1373-80. (Pubitemid 40734272)
7. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 2007 ; 335: 974.
8. Pouta A, Hartikainen AL, Sovio U, Gissler M, Laitinen J, McCarthy MI, et al. Manifestations of metabolic syndrome after hypertensive pregnancy. Hypertension 2004 ; 43: 825-31. (Pubitemid 38405595)
9. McDonald SD, Malinowski A, Zhou Q, Yusuf S, Devereaux PJ. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J 2008 ; 156: 918-30.
10. WHO/OMS. Programme of Work 2004-2008 of Department of Reproductive Health and Research. Genève: WHO/OMS, 2003.
11. Broughton Pipkin F, Rubin PC. Pre-eclampsia: the "disease of theories". Br Med Bull 1994 ; 50: 381-96.
12. Widmer M, Villar J, Benigni A, Conde-Agudelo A, Karumanchi SA, Lindheimer M. Mapping the theories of preeclampsia and the role of angiogenic factors: a systematic review. Obstet Gynecol 2007 ; 109: 168-80. (Pubitemid 46035522)
13. Sibai BM. Hypertensive disorders of pregnancy: the United States perspective. Curr Opin Obstet Gynecol 2008 ; 20: 102-6. (Pubitemid 351498758)
14. Ilekis JV, Reddy UM, Roberts JM. Preeclampsia-a pressing problem: an executive summary of a National Institute of Child Health and Human Development workshop. Reprod Sci 2007 ; 14: 508-23. (Pubitemid 351168783)
15. Chandiramani M, Shennan A. Hypertensive disorders of pregnancy: a UK-based perspective. Curr Opin Obstet Gynecol 2008 ; 20: 96-101. (Pubitemid 351498757)
16. von Dadelszen P, Magee L. What matters in preeclampsia are the associated adverse outcomes: the view from Canada. Curr Opin Obstet Gynecol 2008 ; 20: 110-5. (Pubitemid 351498760)
17. Lockwood C. Predicting Premature delivery: no easy task. N Engl J Med 2002 ; 346: 282-4. (Pubitemid 34438870)
18. Liu A,Wen S, Bottomley J,Walker M, Smith G. Utilization of health care services of pregnant women complicated by preeclampsia in Ontario. Hypertens Pregnancy 2009 ; 28: 76-84.
19. Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007: CD004659.
20. Hofmeyr G, Duley L, Atallah A. Dietary calcium supplementation for prevention of pre-eclampsia and related problems: a systematic review and commentary. BJOG 2007 ; 114: 933-43. (Pubitemid 47052743)
21. Bar J, Ben-Haroush A, Feldberg D, Hod M. The pharmacologic approach to the prevention of preeclampsia: from antiplatelet, antithrombosis and antioxidant therapy to anticonvulsants. Curr Med Chem Cardiovasc Hematol Agents 2005 ; 3: 181-5. (Pubitemid 40974778)
22. Sergio F, Maria Clara DA, Gabriella F. Prophylaxis of recurrent preeclampsia: low-molecular-weight heparin plus low-dose aspirin versus low-dose aspirin alone. Hypertens Pregnancy 2006 ; 25: 115-27. (Pubitemid 44180352)
23. Bujold E, Morency AM, Roberge S, Lacasse Y, Forest JC, Giguère Y. Acetylsalicylic acid for the prevention of preeclampsia and intra-uterine growth restriction inwomen with abnormal uterine artery Doppler: a systematic reviewand meta-analysis. J Obstet Gynaecol Can 2009 ; 31: 818-26.
24. Conde-Agudelo A, Villar J, Lindheimer M. World Health Organization systematic review of screening tests for preeclampsia. Obstet Gynecol 2004 ; 104: 1367-91. (Pubitemid 40458737)
25. Cnossen JS, van der Post JA, Mol BW, Khan KS, Meads CA, ter Riet G. Prediction of pre-eclampsia: a protocol for systematic reviews of test accuracy. BMC Pregnancy Childbirth 2006 ; 6: 29.
26. Meads CA, Cnossen JS, Meher S, Juarez-Garcia A, ter Riet G, Duley L, et al. Methods of prediction and prevention of pre-eclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess 2008 ; 12: iii-iv, 1-270.
27. Thangaratinam S, Coomarasamy A, Sharp S, O'Mahony F, O'Brien S, Ismail KM, et al. Tests for predicting complications of pre-eclampsia: a protocol for systematic reviews. BMC Pregnancy Childbirth 2008 ; 8: 38.
28. Papanna R, Mann LK, Kouides RW, Glantz JC. Protein/creatinine ratio in preeclampsia: a systematic review. Obstet Gynecol 2008 ; 112: 135-44.
29. Whiting P, Rutjes AW, Dinnes J, Reitsma J, Bossuyt PM, Kleijnen J. Development and validation of methods for assessing the quality of diagnostic accuracy studies. Health Technol Assess 2004 ; 8: iii, 1-234.
30. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003 ; 3: 25.
31. Whiting PF, Weswood ME, Rutjes AW, Reitsma JB, Bossuyt PN, Kleijnen J. Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. Med Res Methodol 2006 ; 6: 9.
32. Akolekar R, Minekawa R, Veduta A, Romero XC, Nicolaides KH. Maternal plasma inhibin A at 11-13 weeks of gestation in hypertensive disorders of pregnancy. Prenatal Diagn 2009 ; 29: 753-60.
33. Leal AM, Poon LC, Frisova V, Veduta A, Nicolaides KH. First-trimester maternal serum tumor necrosis factor receptor-1 and preeclampsia. Ultrasound Obstet Gynecol 2009 ; 33: 135-41.
34. Nicolaides KH, Bindra R, Turan OM, Chefetz I, Sammar M, Meiri H, et al. A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound. Ultrasound Obstet Gynecol 2006 ; 27: 13-7. (Pubitemid 43129084)
35. Poon LC, Kametas NA, Maiz N, Akolekar R, Nicolaides KH. Firsttrimester prediction of hypertensive disorders in pregnancy. Hypertension 2009 ; 53: 812-8.
36. Poon LC, Maiz N, Valencia C, Plasencia W, Nicolaides KH. Firsttrimester maternal serum pregnancy-associated plasma protein-A and preeclampsia. Ultrasound Obstet Gynecol 2009 ; 33: 23-33.
37. Poon LC, Nekrasova E, Anastassopoulos P, Livanos P, Nicolaides KH. First-trimester maternal serum matrix metalloproteinase-9 (MMP-9) and adverse pregnancy outcome. Prenatal Diagn 2009 ; 29: 553-9.
38. Romero R, Kusanovic JP, Than NG, Erez O, Gotsch F, Espinoza J, et al. First-trimester maternal serum PP13 in the risk assessment for preeclampsia. Am J Obstet Gynecol 2008 ; 199: 122 e1-122 e11.
39. Spencer K, Cowans NJ, Chefetz I,Tal J, Meiri H. First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia. Ultrasound Obstet Gynecol 2007 ; 29: 128-34. (Pubitemid 46326583)
40. Leeflang M, Reitsma J, Scholten R, Rutjes A, Di Nisio M, Deeks J, et al. Impact of adjustment for quality on results of metaanalyses of diagnostic accuracy. Clin Chem 2007 ; 53: 164-72. (Pubitemid 46338259)
41. Rutjes AW, Reitsma JB, Di Nisio M, Smidt N, van Rijn JC, Bossuyt PM. Evidence of bias and variation in diagnostic accuracy studies. CMAJ 2006 ; 174: 469-76.
42. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. The Standards for Reporting of Diagnostic Accuracy Group. Croat Med J 2003 ; 44: 639-50. (Pubitemid 37392154)
43. Jauniaux E, Gulbis B, Tunkel S, Ramsay B, Campbell S, Meuris S. Maternal serum testing for alpha-fetoprotein and human chorionic gonadotropin in high-risk pregnancies. Prenat Diagn 1996 ; 16: 1129-35. (Pubitemid 27007634)
44. Merviel P, Muller F, Guibourdenche J, Berkane N, Gaudet R, Breart G, et al. Correlations between serum assays of human chorionic gonadotropin (hCG) and human placental lactogen (hPL) and pre-eclampsia or intrauterine growth restriction (IUGR) among nulliparas younger than 38 years. Eur J Obstet Gynecol Reprod Biol 2001 ; 95: 59-67. (Pubitemid 32208671)
45. Chung JE, Cho JS, Han SS, Park YW, Kim JW. Uterine artery Doppler velocimetry in the prediction of adverse obstetric outcomes in unexplained MSAFP elevations. Yonsei Med J 2000 ; 41: 17-21.
46. Kuo PL, Lin CC, Lin YH, Guo HR. Placental sonolucency and pregnancy outcome inwomen with elevated second trimester serum alphafetoprotein levels. J Formos Med Assoc 2003 ; 102: 319-25.
47. Williams MA, Hickok DE, Zingheim RW, Luthy DA, Kimelman J, Nyberg DA, et al. Elevated maternal serum alpha-fetoprotein levels and midtrimester placental abnormalities in relation to subsequent adverse pregnancy outcomes. Am J Obstet Gynecol 1992 ; 167: 1032-7.
48. Aquilina J, Thompson O, Thilaganathan B, Harrington K. Improved early prediction of pre-eclampsia by combining second-trimester maternal serum inhibin-A and uterine artery Doppler. Ultrasound Obstet Gynecol 2001 ; 17: 477-84. (Pubitemid 32575095)
49. Spencer K, Cowans NJ, Stamatopoulou A. ADAM12s in maternal serum as a potential marker of pre-eclampsia. Prenatal Diagn 2008 ; 28: 212-6. (Pubitemid 351427940)
50. Florio P, Reis FM, Pezzani I, Luisi S, Severi FM, Petraglia F. The addition of activin A and inhibin A measurement to uterine artery Doppler velocimetry to improve the early prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2003 ; 21: 165-9. (Pubitemid 36286604)
51. Stepan H, Unversucht A,Wessel N, Faber R. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension 2007 ; 49: 818-24. (Pubitemid 351664216)
52. Diab AE, El-Behery MM, Ebrahiem MA, Shehata AE. Angiogenic factors for the prediction of pre-eclampsia in women with abnormal midtrimester uterine artery Doppler velocimetry. Int J Gynaecol Obstet 2008 ; 102: 146-51.
53. Stepan H, Geipel A, Schwarz F, Kramer T, Wessel N, Faber R. Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. Am J Obstet Gynecol 2008 ; 198: 175 e1-e1756.
54. Florio P, D'Aniello G, Sabatini L, Severi FM, Fineschi D, Bocchi C, et al. Factor II: C activity and uterine artery Doppler evaluation to improve the early prediction of pre-eclampsia on women with gestational hypertension. J Hypertens 2005 ; 23: 141-6. (Pubitemid 40128992)
55. Anastasakis E, Papantoniou N, Daskalakis G, Mesogitis S, Antsaklis A. Screening for pre-eclampsia by oxidative stress markers and uteroplacental blood flow. J Obstet Gynaecol 2008 ; 28: 285-9. (Pubitemid 351873795)
56. Audibert F, Benchimol Y, Benattar C, Champagne C, Frydman R. Prediction of preeclampsia or intrauterine growth restriction by second trimester serum screening and uterine Doppler velocimetry. Fetal Diagn Ther 2005 ; 20: 48-53. (Pubitemid 40082185)
57. Ay E, Kavak ZN, Elter K, Gokaslan H, Pekin T. Screening for preeclampsia by using maternal serum inhibin A, activin A, human chorionic gonadotropin, unconjugated estriol, and alpha-fetoprotein levels and uterine artery Doppler in the second trimester of pregnancy. Aust N Z J Obstet Gynaecol 2005 ; 45: 283-8. (Pubitemid 41122589)
58. + 6 weeks' gestation. Ultrasound Obstet Gynecol 2006 ; 27: 658-63. (Pubitemid 43967369)
59. Spencer K, Cowans NJ, Chefetz I, Tal J,Kuhnreich I, Meiri H. Secondtrimester uterine artery Doppler pulsatility index and maternal serum PP13 as markers of pre-eclampsia. Prenatal Diagn 2007 ; 27: 258-63. (Pubitemid 46450585)
60. Spencer K,Yu CK, Cowans NJ, Otigbah C, Nicolaides KH. Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler. Prenatal Diagn 2005 ; 25: 949-53. (Pubitemid 41494994)
61. Espinoza J, Romero R, Nien JK, Gomez R, Kusanovic JP, Goncalves LF, et al. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol 2007 ; 196: 326 e1-326 13.
62. Onalan R, Onalan G, Gunenc Z, Karabulut E. Combining 2ndtrimester maternal serum homocysteine levels and uterine artery Doppler for prediction of preeclampsia and isolated intrauterine growth restriction. Gynecol Obstet Invest 2006 ; 61: 142-8.
63. Liu SS, Lee FK, Lee JL, Tsai MS, Cheong ML, She BQ, et al. Pregnancy outcomes in unselected singleton pregnant women with an increased risk of first-trimester Down's syndrome. Acta Obstet Gynecol Scand 2004 ; 83: 1130-4. (Pubitemid 39626187)
64. Savvidou MD, Yu CK, Harland LC, Hingorani AD, Nicolaides KH. Maternal serum concentration of soluble fms-like tyrosine kinase 1 and vascular endothelial growth factor in women with abnormal uterine artery Doppler and in those with fetal growth restriction. Am J Obstet Gynecol 2006 ; 195: 1668-73. (Pubitemid 44792614)
65. Parra M, Rodrigo R, Barja P, Bosco C, Fernandez V, Munoz H, et al. Screening test for preeclampsia through assessment of uteroplacental blood flow and biochemical markers of oxidative stress and endothelial dysfunction. Am J Obstet Gynecol 2005 ; 193: 1486-91. (Pubitemid 41395121)
66. Yu CK, Lakasing L, Papageorghiou AT, Spencer K, Nicolaides KH. Uterine artery Doppler and mid-trimester maternal plasma homocysteine in subsequent pre-eclampsia. J Matern Fetal Neonatal Med 2004 ; 16: 134-9. (Pubitemid 39487614)
67. Savvidou MD, Noori M, Anderson JM, Hingorani AD, Nicolaides KH. Maternal endothelial function and serum concentrations of placental growth factor and soluble endoglin in women with abnormal placentation. Ultrasound Obstet Gynecol 2008 ; 32: 871-6.
68. Prefumo F, Thilaganathan B, Whitley GS. First-trimester uterine artery resistance and maternal serum concentration of asymmetric dimethylarginine. Ultrasound Obstet Gynecol 2008 ; 31: 153-7.
69. Savvidou MD, Lees CC, Parra M, Hingorani AD, Nicolaides KH. Levels of C-reactive protein in pregnantwomen who subsequently develop pre-eclampsia. BJOG 2002 ; 109: 297-301. (Pubitemid 37329304)
70. Savvidou MD, Sotiriadis A, Kaihura C, Nicolaides KH, Sattar N. Circulating levels of adiponectin and leptin at 23-25 weeks of pregnancy in women with impaired placentation and in those with established fetal growth restriction. Clin Sci (Lond) 2008 ; 115: 219-24.
71. Tommaselli GA, Pighetti M, Nasti A, D'Elia A, Guida M, Di Carlo C, et al. Serum leptin levels and uterine Doppler flow velocimetry at 20 weeks' gestation as markers for the development of pre-eclampsia. Gynecol Endocrinol 2004 ; 19: 160-5. (Pubitemid 39486903)
72. Spencer K, Cowans NJ, Nicolaides KH. Maternal serum inhibin-A and activin-A levels in the first trimester of pregnancies developing preeclampsia. Ultrasound Obstet Gynecol 2008 ; 32: 622-6.